New data from a retrospective study with aspirine in advanced colorectal cancer patients

News source: 
Anticancer Fund

The use of aspirin to treat cancer remains a topic of immense scientific and public interest. New data from a retrospective study in advanced colorectal cancer patients taking aspirin concurrently indicates that it may have some positive effects on clinical outcomes. Giampieri and colleagues assessed the records of 63 patients with metastatic colorectal cancer who had failed standard treatment and were being treated with oral capecitabine as salvage therapy. Twenty of these patients were also receiving daily aspirin (100 mg/day) for other conditions. Comparison between the two groups showed that aspirin patients had a greater disease control rate (80% vs 30%, P = 0.000377), increased progression free survival (6.5 vs 3.3 months, hazard ratio = 0.48; 95% CI, 0.30-0.79; P =0 .0042) and improved overall survival (median overall survival, 14.7 vs. 8.7 months, hazard ratio = 0.43; 95% confidence interval, 0.26-0.72; P = 0.0023). This data suggests that aspirin may improve outcomes for patients treated with capecitabine, and that prospective randomised trials are required to confirm the effects.

 

Source: (abstract only)

https://www.ncbi.nlm.nih.gov/pubmed/27576095